Skip to main content
TipRanks
Go Ultimate75% OFF

Arrail Group Ltd. (6639) AI Stock Analysis

1 Followers
HK:6639

Arrail Group Ltd.

(HKEX:6639)

Select Model
Rating:60Neutral
Price Target:HKD 2.00â–²(9.35% Upside)
Action:reiterated
Date:03/24/26

The score is driven primarily by improving fundamentals and solid cash generation, supporting a credible turnaround, but upside is constrained by still-thin profitability/low ROE and a slightly softer 2025 revenue trend. Technically the stock looks range-bound, and the high P/E without a dividend meaningfully weighs on the overall rating.

Positive Factors
Strong cash generationConsistent positive operating and free cash flow, with FCF up about 21% in 2025 and FCF ~0.75x net income, gives the business durable internal funding. This reduces reliance on external finance, supports reinvestment in clinics and tech, and underpins a credible turnaround.
Negative Factors
Very thin profitabilityExtremely low net margins and ROE leave the business exposed: small cost increases or volume declines can wipe out profits. Thin earnings power constrains reinvestment, limits ability to build reserves, and makes sustained improvement dependent on structural margin expansion.

Arrail Group Ltd. (6639) vs. iShares MSCI Hong Kong ETF (EWH)

-2%0%3%5%8%10%13%15%18%HK:6639+11.52%EWH+8.61%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
HKD 1.03B
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
31.1
Beta (1Y)
1.00
Revenue Growth
―
EPS Growth
―
Country
Hong Kong
Employees
3,296
Sector
Healthcare
Sector Strength
51
Industry
Medical - Care Facilities

Arrail Group Ltd. Business Overview & Revenue Model

Company Description

Arrail Group Limited is a Chinese healthcare provider that manages a network of dental clinics and hospitals. It conducts its operations primarily through two brand identities: Arrail Dental and Rytime Dental. The company delivers a comprehensive sui...

Arrail Group Ltd. Financial Statement Overview

Summary

Turnaround is evident with profitability improving from 2022–2023 losses to modest profits in 2024–2025 and consistently positive operating/free cash flow. Offsetting this are slightly declining 2025 revenue, very thin net margin (~1.3%), and low ROE (~1.3%), which make results vulnerable to cost and volume swings.

Income Statement

62Positive

Balance Sheet

58Neutral

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMMar 2024Mar 2023Mar 2022Mar 2022Mar 2021
Income Statement
Total Revenue1.69B1.69B1.75B1.62B1.47B1.52B
Gross Profit342.09M342.09M392.68M336.56M247.08M364.42M
EBITDA314.83M312.65M322.35M-417.14M87.85M-300.84M
Net Income21.99M21.99M17.16M-701.03M-219.91M-599.42M
Balance Sheet
Total Assets3.16B3.16B3.25B2.99B3.06B2.35B
Cash, Cash Equivalents and Short-Term Investments1.09B1.09B1.10B1.26B937.53M727.31M
Total Debt1.03B1.03B1.05B890.67M955.68M1.03B
Total Liabilities1.38B1.38B1.42B1.38B1.37B4.81B
Stockholders Equity1.71B1.71B1.76B1.56B1.61B-2.50B
Cash Flow
Free Cash Flow181.98M172.69M184.21M108.63M23.50M213.50M
Operating Cash Flow234.02M231.14M276.65M224.28M131.66M242.87M
Investing Cash Flow-182.75M-153.52M-176.00M-203.94M-342.44M61.75M
Financing Cash Flow-188.74M-206.84M-106.96M380.86M-280.35M217.51M

Arrail Group Ltd. Technical Analysis

Technical Analysis SentimentPositive
Last Price1.83

Price Trends

50DMA1.83Positive
100DMA1.83Negative
200DMA1.83Positive

Market Momentum

MACD0.00Positive
STOCH30.77Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6639, the sentiment is Positive. The current price of 1.83 is below the 20-day moving average (MA) of 1.83, below the 50-day MA of 1.83, and below the 200-day MA of 1.83, indicating a bullish trend. The MACD of 0.00 indicates Positive momentum. The RSI at is Neutral, neither overbought nor oversold. The STOCH value of 30.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6639.

Arrail Group Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

HK:6639 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HK:2373HK:237378OutperformHKD 4.53B9.5931.63%3.99%22.71%43.58%
HK:3309HK:330976OutperformHKD 1.21B11.225.57%3.17%4.75%―
HK:2219HK:221970OutperformHKD 1.65B8.326.97%10.31%3.85%-1.23%
HK:6639HK:663960NeutralHKD 1.03B31.111.27%―――
HK:1846HK:184655NeutralHKD 620.36M251.950.20%2.27%20.54%-96.74%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%HK:6639HK:1846HK:2219HK:2279HK:2373HK:3309Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HK:6639 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HK:6639Arrail Group Ltd.1.830.2012.21%
HK:1846EuroEyes International Eye Clinic Limited1.88-1.28-40.56%
HK:2219Chaoju Eye Care Holdings Ltd.2.33-0.02-0.68%
HK:2279Yonghe Medical Group Co., Ltd.2.140.3922.22%
HK:2373Beauty Farm Medical & Health Industry, Inc.17.64-9.75-35.61%
HK:3309C-MER Eye Care Holdings Limited0.93-0.75-44.54%

Arrail Group Ltd. Corporate Events

Arrail delays interim results as probe and auditor change drag on

Mar 2, 2026

Arrail Group Limited has provided a quarterly update on the ongoing independent investigation into historical loans, repayments and related payments, noting that investigators have substantially completed major work streams but have faced delays due...

Arrail Replaces PwC as Auditor Amid Delayed Interim Review and Ongoing Probe

Feb 15, 2026

Arrail Group Limited has announced the resignation of PricewaterhouseCoopers as its auditor, following delays in the review of the group’s interim financial information for the six months ended September 30, 2025 and ongoing independent investigation...

Arrail Group Extends Interim Results Delay Amid Forensic Probe Into Related Transactions

Jan 21, 2026

Arrail Group Limited has announced further delays to the publication of its interim results for the six months ended 30 September 2025 and the dispatch of its 2025 interim report, and confirmed that trading in its shares will remain suspended. The de...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Mar 24, 2026